Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 08 04:00PM ET
1.68
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-0.77 Insider Own3.44% Shs Outstand361.49M Perf Week6.33%
Market Cap607.30M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float349.07M Perf Month0.60%
Income-200.59M PEG- EPS next Q-0.16 Inst Own76.87% Short Float7.63% Perf Quarter3.07%
Sales3.64M P/S166.84 EPS this Y14.47% Inst Trans74.88% Short Ratio9.26 Perf Half Y-18.84%
Book/sh0.66 P/B2.53 EPS next Y16.92% ROA-58.14% Short Interest26.63M Perf Year55.56%
Cash/sh0.86 P/C1.96 EPS next 5Y- ROE-94.10% 52W Range0.92 - 3.73 Perf YTD9.80%
Dividend Est.- P/FCF- EPS past 5Y6.80% ROI-58.25% 52W High-54.96% Beta1.27
Dividend TTM- Quick Ratio11.49 Sales past 5Y186.21% Gross Margin76.52% 52W Low82.61% ATR (14)0.09
Dividend Ex-Date- Current Ratio11.51 EPS Y/Y TTM-13.01% Oper. Margin-5412.11% RSI (14)53.12 Volatility4.81% 5.17%
Employees285 Debt/Eq0.44 Sales Y/Y TTM792.40% Profit Margin-5509.34% Recom1.67 Target Price6.20
Option/ShortYes / Yes LT Debt/Eq0.43 EPS Q/Q21.61% Payout- Rel Volume0.49 Prev Close1.68
Sales Surprise-52.06% EPS Surprise3.95% Sales Q/Q419.56% EarningsAug 01 AMC Avg Volume2.87M Price1.68
SMA203.32% SMA50-0.54% SMA200-10.72% Trades Volume1,404,304 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jun-17-24Initiated H.C. Wainwright Buy $10
Apr-30-24Initiated Leerink Partners Outperform $5
Mar-07-23Initiated Jefferies Hold $3
Aug-12-22Initiated Piper Sandler Overweight $10
Jan-29-21Upgrade JP Morgan Underweight → Neutral $7
Jan-29-21Downgrade Wedbush Outperform → Neutral $2 → $8
Dec-08-20Upgrade Citigroup Neutral → Buy
Nov-18-20Upgrade Gabelli & Co Hold → Buy
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Sep-27-24 08:00AM
Sep-16-24 08:00AM
Sep-10-24 08:00AM
Sep-03-24 04:00PM
08:00AM
10:26PM Loading…
Sep-01-24 10:26PM
Aug-29-24 08:41PM
Aug-22-24 11:26AM
10:33AM
Aug-21-24 08:00AM
Aug-14-24 12:33PM
Aug-13-24 08:30AM
07:00AM
Aug-07-24 08:00AM
Aug-01-24 05:15PM
04:12PM Loading…
04:12PM
04:00PM
Jul-25-24 08:00AM
Jul-17-24 11:15AM
Jul-16-24 08:00AM
Jul-15-24 08:00AM
Jul-08-24 09:15AM
Jun-21-24 08:00AM
Jun-19-24 08:00AM
Jun-18-24 08:00AM
Jun-14-24 08:00AM
May-30-24 04:45AM
May-29-24 07:30AM
May-14-24 08:03AM
07:00AM
07:30AM Loading…
May-09-24 07:30AM
May-06-24 10:05AM
May-03-24 07:46AM
04:07AM
May-02-24 08:59PM
06:05PM
06:03PM
05:00PM
04:05PM
Apr-29-24 10:42AM
09:00AM
07:00AM
Apr-18-24 08:00AM
Apr-16-24 12:00PM
Apr-03-24 08:00AM
Mar-25-24 09:20AM
Mar-13-24 12:45PM
Mar-12-24 08:00AM
Mar-11-24 08:25AM
07:34AM
07:15AM
07:05AM
07:00AM
Feb-29-24 10:00AM
Feb-22-24 12:58PM
Jan-31-24 05:06AM
Jan-23-24 05:21AM
Jan-08-24 07:00AM
Dec-26-23 05:06AM
Dec-21-23 04:15PM
Nov-30-23 07:30AM
Nov-22-23 07:30AM
Nov-15-23 01:03AM
Nov-12-23 02:10PM
Nov-10-23 04:01PM
10:53AM
Nov-08-23 09:45PM
07:19AM
07:00AM
Nov-03-23 09:00AM
Nov-02-23 09:00AM
Nov-01-23 09:00AM
Oct-31-23 04:01PM
Oct-30-23 04:01PM
Oct-25-23 08:45AM
Oct-17-23 04:01PM
01:35PM
Oct-13-23 11:38AM
Oct-11-23 11:13AM
09:00AM
Oct-10-23 11:25AM
09:44AM
03:33AM
Oct-09-23 04:01PM
08:00AM
Sep-28-23 09:00AM
Sep-26-23 09:00AM
Sep-20-23 12:28PM
Sep-14-23 09:40PM
Sep-07-23 04:30PM
09:00AM
Aug-21-23 09:00AM
Aug-17-23 09:56AM
Aug-08-23 09:00AM
Aug-04-23 09:12AM
Aug-03-23 05:15PM
04:10PM
04:01PM
Jul-28-23 04:01PM
08:00AM
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COATS LONNELFormer AffiliateAug 15 '24Proposed Sale1.60300,000480,000Aug 15 04:47 PM
Swain Judith LDirectorApr 28 '24Option Exercise0.008,032048,364Apr 29 04:21 PM
SOBECKI CHRISTOPHER JDirectorApr 28 '24Option Exercise0.008,0320167,055Apr 29 04:20 PM
LEFKOWITZ ROBERT J MDDirectorApr 28 '24Option Exercise0.008,032048,364Apr 29 04:18 PM
DEBBANE RAYMONDDirectorApr 28 '24Option Exercise0.008,03201,348,879Apr 29 04:17 PM
BARKER SAM LDirectorApr 28 '24Option Exercise0.008,032087,649Apr 29 04:17 PM
Amouyal PhilippeDirectorApr 28 '24Option Exercise0.008,0320248,364Apr 29 04:16 PM
COATS LONNELChief Executive OfficerNov 16 '23Buy1.0590,00094,797914,359Nov 17 04:55 PM
COATS LONNELChief Executive OfficerNov 10 '23Buy1.0110,00010,100824,359Nov 13 05:31 PM
DEBBANE RAYMONDDirectorOct 10 '23Buy1.14508,306579,367849,153Oct 12 04:01 PM
DEBBANE RAYMONDDirectorOct 11 '23Buy1.08342,874370,7841,192,027Oct 12 04:01 PM
DEBBANE RAYMONDDirectorOct 12 '23Buy1.03148,820153,8051,340,847Oct 12 04:01 PM